Floatz logo

Golidocitinib

Natural Killer/T-cell Lymphoma

Beijing Tongren HospitalSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

52 Active assets in the Natural Killer/T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
PEGASPARGASE
CStone Pharmaceuticals
Phase 4BBB
DEXAMETHASONE
Mingzhi Zhang
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Centre, Singapore
Phase 4BBB
ETOPOSIDE
Tarapeutics Science Inc.
Phase 4BB
Tucidinostat
Ruijin Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Golidocitinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
63 / 100
View asset →
mature T-cell and NK-cell non-Hodgkin lymphomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →